Enhancing the quality of life of pets and strengthening the human-animal bond is at the core of an upcoming biologics manufacturing development.
Elanco Animal Health Incorporated has announced it will spend $130 million through 2026 to grow its monoclonal antibody (mAb) platform, funding a 25,000-square-foot facility expansion in Elwood, Kans. Currently, the facility manufactures and ships the company’s Canine Parvovirus Monoclonal Antibody (CPMA), the first and only USDA conditionally approved, targeted treatment for canine parvovirus.
“Elanco’s R&D strategy is centered around a consistent flow of high-impact innovation in key markets,” says Ellen de Brabander, PhD, executive vice president, Research and Development for Elanco. Further, Dr. Brabander cites the “untapped potential” of monoclonals in animal health. “We believe the monoclonal platform is a key path to deliver these new, high impact innovations—and [this] news about our investment to expand the Elwood site creates the footprint we need to scale up and manufacture our future innovation portfolio,”
A treatment for canine dermatology is reported by the company as its next monoclonal antibody, expected in 2025.
Alongside doubling production capacity at the manufacturing facility with advanced upstream and downstream processing equipment, the project will also include:
- A new pilot plant to expedite product pipeline delivery
- A new quality control laboratory
- Expanded support spaces
For more information, visit the Elanco website.